Pancerebellitis Under Immunotherapy With Pembrolizumab.
作者信息
Koch Myriam, Rennert Janine, Schulz Christian
出版信息
Dtsch Arztebl Int. 2022 Nov 25;119(47):820. doi: 10.3238/arztebl.m2022.0228.
Abstract
摘要
相似文献
1
Pancerebellitis Under Immunotherapy With Pembrolizumab.帕博利珠单抗免疫治疗下的全小脑炎
Dtsch Arztebl Int. 2022 Nov 25;119(47):820. doi: 10.3238/arztebl.m2022.0228.
2
Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.在肺癌患者中使用 Pembrolizumab 治疗期间甲状腺癌的发展。
Ann Thorac Surg. 2020 Jun;109(6):e397-e399. doi: 10.1016/j.athoracsur.2019.10.059. Epub 2019 Dec 14.
3
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.老年女性非小细胞肺癌患者应用帕博利珠单抗治疗后发生大疱性类天疱疮：病例报告及文献复习。
J Oncol Pharm Pract. 2021 Apr;27(3):727-733. doi: 10.1177/1078155220946370. Epub 2020 Aug 9.
4
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.基于药物的评分在接受一线免疫治疗的晚期非小细胞肺癌患者中的预测能力。
Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
5
Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.免疫相关不良反应与巩固性帕博利珠单抗治疗不可切除 III 期非小细胞肺癌患者放化疗后疗效结局的相关性。
Clin Lung Cancer. 2021 Jul;22(4):274-281. doi: 10.1016/j.cllc.2020.12.014. Epub 2021 Jan 23.
6
Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab.仅90毫克阿替利珠单抗极低剂量引发的免疫疗法相关肝炎和血小板减少症。
Eur J Cancer. 2020 Jul;133:22-24. doi: 10.1016/j.ejca.2020.04.008. Epub 2020 May 15.
7
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.高 PD-L1 表达的非小细胞肺癌伴脑转移患者，帕博利珠单抗引起免疫相关不良反应后生存和疾病控制得到改善。
J Neurooncol. 2021 Mar;152(1):125-134. doi: 10.1007/s11060-020-03686-3. Epub 2021 Jan 7.
8
COVID-19: the use of immunotherapy in metastatic lung cancer.新型冠状病毒肺炎：免疫疗法在转移性肺癌中的应用
Immunotherapy. 2020 Jun;12(8):545-548. doi: 10.2217/imt-2020-0096. Epub 2020 Apr 30.
9
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.派姆单抗输注后消失的胆管综合征：病例报告及文献复习。
Immunotherapy. 2022 Mar;14(4):175-181. doi: 10.2217/imt-2021-0078. Epub 2021 Dec 7.
10
Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy.对“帕博利珠单抗联合CC-486与帕博利珠单抗联合安慰剂治疗既往治疗过的晚期非小细胞肺癌患者的随机2期研究”的评论——不支持免疫治疗降阶梯
Eur J Cancer. 2019 Jul;115:24-26. doi: 10.1016/j.ejca.2019.04.011. Epub 2019 May 10.
引用本文的文献
1
Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors.传统中药及其成分可有效降低免疫检查点抑制剂介导的耐药性。
Front Immunol. 2024 Nov 26;15:1429483. doi: 10.3389/fimmu.2024.1429483. eCollection 2024.
2
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia.免疫检查点抑制剂相关小脑毒性：临床特征及与副肿瘤性小脑炎的比较。
Cerebellum. 2024 Dec;23(6):2308-2323. doi: 10.1007/s12311-024-01727-5. Epub 2024 Aug 17.
Zotero 插件